Literature DB >> 6119011

Serotonin and dopamine synthesis in phenylketonuria.

H C Curtius, A Niederwieser, M Viscontini, W Leimbacher, H Wegmann, B Blehova, F Rey, J Schaub, H Schmidt.   

Abstract

Two regulation systems of the serotonin and dopamine biosynthesis in patients with classical and atypical PKU were investigated. In classical PKU, the serotonin and dopamine biosynthesis is inhibited by high L-phenylalanine in blood and tissues. The dopamine formation in vivo was inhibited by phenylalanine blood concentrations higher than 25 mg/dl: the serotonin formation was inhibited even at a phenylalanine blood concentration of only 8 mg/dl. In two patients with dihydrobiopterin synthetase deficiency, the dopamine, and even more pronounced the serotonin, excretions are considerably reduced. The dopamine excretion was reduced to about 50% and the serotonin excretion to only 10% compared to controls. Under BH4 therapy (16 mg daily), the dopamine values increased about twice, serotonin threefold and the phenylalanine blood concentration normalized to 1-1.5 mg/dl. On loading a patient with BH2 synthetase deficiency with 50 mg/kg deuterated tryptophan-d5 and 150 mg/kg deuterated tyrosine d2 (phenylalanine blood concentration of 16 mg/dl), deuterated dopamine d1 and serotonin d4 could only be formed in detectable amounts after BH4 administration. During BH4 therapy the amount of dopamine d1 and serotonin d4 formed was lower than but comparable to normal controls.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6119011     DOI: 10.1007/978-1-4684-3860-4_16

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  16 in total

Review 1.  Oxidative stress in phenylketonuria: what is the evidence?

Authors:  Graziela S Ribas; Angela Sitta; Moacir Wajner; Carmen R Vargas
Journal:  Cell Mol Neurobiol       Date:  2011-04-23       Impact factor: 5.046

Review 2.  The role of the blood-brain barrier in the aetiology of permanent brain dysfunction in hyperphenylalaninaemia.

Authors:  F A Hommes
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

3.  Tetrahydrobiopterin treatment reduces brain L-Phe but only partially improves serotonin in hyperphenylalaninemic ENU1/2 mice.

Authors:  Tanja Scherer; Gabriella Allegri; Christineh N Sarkissian; Ming Ying; Hiu Man Grisch-Chan; Anahita Rassi; Shelley R Winn; Cary O Harding; Aurora Martinez; Beat Thöny
Journal:  J Inherit Metab Dis       Date:  2018-03-08       Impact factor: 4.982

4.  Prolactin, a marker for cerebral dopamine deficiency in patients suffering from phenylketonuria (PKU)?

Authors:  J Denecke; W Schlegel; G H Koch; R Feldmann; E Harms; J Weglage
Journal:  J Inherit Metab Dis       Date:  2000-12       Impact factor: 4.982

5.  Neuroblastoma in a patient with dihydropteridine reductase deficiency.

Authors:  L G Greeves; R J Leeming; K Hyland; S I Dempsey; D J Carson
Journal:  Eur J Pediatr       Date:  1990-07       Impact factor: 3.183

Review 6.  Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders.

Authors:  Dominic J Gessler; Guangping Gao
Journal:  Methods Mol Biol       Date:  2016

7.  High dose sapropterin dihydrochloride therapy improves monoamine neurotransmitter turnover in murine phenylketonuria (PKU).

Authors:  Shelley R Winn; Tanja Scherer; Beat Thöny; Cary O Harding
Journal:  Mol Genet Metab       Date:  2015-11-26       Impact factor: 4.797

8.  Content of phenylalanine, tyrosine and their metabolites in CSF in phenylketonuria.

Authors:  A G Antoshechkin; T V Chentsova; D B Naritsin; G P Railian
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

9.  Serotonin and noradrenaline concentrations and serotonin uptake in platelets from hyperphenylalaninaemic patients.

Authors:  M Giovannini; R Valsasina; R Longhi; A M Cesura; M D Galva; E Riva; G P Bondiolotti; G B Picotti
Journal:  J Inherit Metab Dis       Date:  1988       Impact factor: 4.982

10.  Biochemical and neuropsychological effects of elevated plasma phenylalanine in patients with treated phenylketonuria. A model for the study of phenylalanine and brain function in man.

Authors:  W Krause; M Halminski; L McDonald; P Dembure; R Salvo; D Freides; L Elsas
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.